Virtual Library
Start Your Search
Konstantina Karagiorgou
Author of
-
+
EP1.12 - Small Cell Lung Cancer/NET (ID 202)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Small Cell Lung Cancer/NET
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.12-14 - Multiple Primary Malignant Neoplasms in Patients with Small Cell Lung Cancer. The Experience of Our Center (Now Available) (ID 715)
08:00 - 18:00 | Author(s): Konstantina Karagiorgou
- Abstract
Background
Treatment and, mainly, modern diagnostic tools during the first diagnosis of the disease and follow-up, seem to improve survival in patients with small cell lung cancer (SCLC) and thus increase the number of patients diagnosed with multiple primary malignant neoplasms.
Method
The aim of this retrospective study was to estimate and report the incidence of multiple primary malignant neoplasms and discuss the clinical characteristics of this subgroup of patients with SCLC.
The study includes all patients consecutively admitted between 1/1983 -3/2019 at the Department of Medical Oncology, Evangelismos General Hospital, Athens, Hellas.
Result
Five hundred fifty eight patients [386(69%) men, 172(31%) women, 285(51%) with limited and 273(49%) with extended disease] were included in the study. Median age was 63 (33-87)years, median ECOG was 2 (0-4) and median time of follow-up was 18+ (1+ - 696+) months. Three hundred ninety six (71%) had a short period of follow-up ≤24 months (group A), while 162 had a period of follow-up >24 months (group B). Multiple primary malignant neoplasms were detected in 23(4%) patients, 20(5%) men and 3 (2%) women (p<0.05), synchronous in 11(48%) and metachronous in 12(52%) patients, p=NS. The second malignant neoplasms were lung adenocarcinoma, squamous cell lung carcinoma, colon adenocarcinoma, bladder transitional cell carcinoma, head and neck squamous cell carcinoma, prostate adenocarcinoma, NHL, and thyroid follicular carcinoma in 7, 5, 4, 3, 2, 1 and 1 cases respectively. In the group of the 285 patients with limited disease 16(6%) multiple primary malignant neoplasms were observed in relation to 7/273(2.5%) of the patients with extensive disease (0.01< p<0.05). The multiple primary neoplasms were 12/396(3%) and 11/162(7%), p <0.05 in patients of the groups A and B respectively.
Conclusion
1. Development of multiple primary malignant carcinomas in patients with SCLC, does not seem to be a rare phenomenon. 2. The great majority of the multiple primary carcinomas (lung adenocarcinomas, squamous cell lung carcinomas, bladder transitional cell carcinomas, head / neck carcinomas) is smoking dependent. 3. The risk was higher in males, in patients with limited disease and in those surviving more than 24 months.
-
+
P2.01 - Advanced NSCLC (ID 159)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.01-61 - Multiple Primary Carcinomas (MPC) in Patients with Non Small Cell Lung Cancer (NSCLC) (ID 914)
10:15 - 18:15 | Author(s): Konstantina Karagiorgou
- Abstract
Background
The improving survival of NSCLC patients, due to: 1. the initial diagnosis in early stages using the newer modern diagnostic tools, 2. the treatment of the disease with new effective antineoplastic drugs, and 3. the remarkable suspicion of the physicians, leads to registry of high incidence ratio of MPC in NSCLC patients.
Method
The aim of the study was the registration of the number and clinical characteristics of MPC in NSCLC patients. Between 4/1986-3/2019, 1756 patients, 1123 (64%)men, 633 (36%)women, median age 64(33-87)years and ECOG 2(0-3) were consequently admitted in our Unit. Stage <IIIA had 304(17%) and ≥IIIA 1452(83%)patients (groups A, B respectively). Median follow-up was 20+(1+-240+)months. Survival ≥5years observed in 351(20%)patients. According to our protocols, patients stage <IIIA, underwent only follow-up after radical surgery, while patients stage IIIA treated with platinum-based chemotherapy(PBC) adjuvantly or neoadjuvantly±locoregionally radiotherapy. Patients stage ≥IIIB received therapeutically PBC±radiotherapy.
Result
Eighty-six patients, 78/1123(7%)men, 8/633(1%)women (p<0.001), developed 102 MPC. The median interval time between NSCLC diagnosis and MPC detection, was 58(0-220)months. Two men experienced by four (all metachronous)MPC. One with lung adenocarcinoma(LADC), developed non-AIDS Kaposi-sarcoma of the leg, MDS and squamous-cell lung cancer(SqCLC). The second, with LADC, developed transitional-cell bladder carcinoma(TCBC), prostate adenocarcinoma(PrC), and colon cancer(CC). Five patients(3 men, 2 women) had by three, metachronous, MPC. One had LADC, NHL, CC, the second LADC, TCBC, PrC, and the third SqCLC, CLL and CC. One woman experienced LADC, lymphopenic HL and breast cancer(BC) and the other LADC, CLL, and small-cell lung carcinoma. Other 79 patients developed 79 MPC, 11(14%)median age 63(51-77)years, synchronous and 68(86%)median age 63.5(34-75)years, metachronous The synchronous were LADC/SqCLC in 2, LADC/PrC in 2, LADC/TCBC in 2, SqCLC/head-neck squamous-cell carcinoma(HNSqCC) in 2, and SqCLC/CC in 3 cases. The metachronous MPC were LADC, CLL, TCBC, SqCLC, PrC, CC, HNSqCC, BC, NHL, HL, in 12, 10, 8, 8, 8, 8, 6, 3, 3, 2, cases respectively. Among 351 patients surviving ≥5years, 40(11%) experienced MPC versus 46/1405(3%) with survival <5years(p <0.001). Seventy-five patients diagnosed with metachronous MPC: 10/304(3%) versus 65/1452(4.5%) of group A and B, (p=NS). There was no statistically significance in the location of non-haematological MPC related to the diaphragm (37 upper, 39 lower the diaphragm).
Conclusion
According to our findings in NSCLC patients: 1. MPC detection is not uncommon, mainly in men. 2. The longer survival enhances the possibility of MPC. This must be considered during the follow-up of those patients. 3. Previous chemoradiotherapy doesn’t increase the risk of MPC.
